Abstract: The present invention is directed to an artificial nucleic acid and to a polypeptide suitable for use in the treatment or prophylaxis of an infection with a flavivirus, in particular an infection with yellow fever virus or with dengue virus, or of a disorder related to such an infection. The present invention is also directed to a composition, preferably an immunogenic composition, comprising the artificial nucleic acid or the inventive polypeptide. In particular, the present invention concerns an immunogenic composition against a flavivirus, such as yellow fever virus or dengue virus. Further, the invention concerns a kit, particularly a kit of parts, comprising the artificial nucleic acid, polypeptide or (immunogenic) composition.

Abstract: Method, apparatus and system for adjusting medicament doses. A method of providing a medication dose adjustment using a computing device comprises: receiving an adjustment cycle time period; receiving a threshold number of dose and blood glucose measurement pairs, the threshold number of dose and blood glucose measurement pairs being less than a total number of potential dose and blood glucose measurement pairs possible in the adjustment time cycle period; receiving a dose and blood glucose measurement pair; determining if a total number of dose and blood glucose measurement pairs received within a current adjustment cycle time period meets the threshold number, the current adjustment cycle time period depending on the received adjustment cycle time period; in response to a positive determination, determining if a dose adjustment is required based on the dose and blood glucose measurement pairs received within an adjustment cycle time period; and outputting the dose adjustment.

Abstract: Generally, the present invention relates to the field of steroid hydroxylation. More specifically, the present invention relates to a method for the 21-hydroxylation of steroids in cells. It also relates to cells expressing a steroid 21-hydroxylating enzyme or steroid 21-hydroxylase, expression vectors comprising a nucleic acid encoding for a steroid 21-hydroxylase and a kit for carrying out the method for the 21-hydroxylation of steroids in cells.

Abstract: Binding proteins comprising a VL region paired with a VH region, and a CH1 region paired with a CL region, wherein the VL region and VH region comprise opposite charged mutations to facilitate pairing, and wherein the CH1 region and CL region comprise mutations to facilitate pairing, are provided. Binding proteins comprising one or more cysteine residues engineered into the VH/VL pair to form one or more disulfide bonds, are also provided. Multispecific binding proteins, nucleic acids encoding binding proteins and multispecific binding proteins, expression vectors, host cells, pharmaceutical composition and methods of treatment administering the binding proteins or multispecific binding proteins described herein are also provided.

Abstract: In one aspect the present disclosure refers to a supplementary device for a manually operable injection device, the supplementary device comprising: a body attachable to an elongated housing of the injection device, at least one connector connected to the body and connectable to the housing, wherein the body is attachable to the housing via the at least one connector, a sensor arrangement coupled to at least one of the body and the at least one connector and configured to measure a longitudinal force component acting between the at least one connector and the body in a direction parallel to the elongation of the housing.

Abstract: The present disclosure relates to an injector device having a housing, a cartridge with a reservoir for medicament, a needle unit with a needle, and a needle sleeve rotatably mounted to the housing about an axis. Prior to use of the injector device the needle is sealed from the reservoir, and at least one of the needle unit and the cartridge is axially slidably mounted to the housing. The needle sleeve includes an engagement member arranged to engage the needle unit and/or the cartridge. The engagement member is adapted such that rotation of the needle sleeve moves the needle unit and/or the cartridge in an axial direction to move the needle into fluid communication with the reservoir.

Abstract: A data collection device comprises at least two optical sensors configured to detect tick marks of a medicament dose indicator of the medicament delivery device in their respective detection areas, and a processing arrangement configured to determine a current medicament dosage programmed into said medicament delivery device based on a count of the tick marks that pass through the detection areas of the optical sensors during programming of said medicament dosage into said medicament delivery device. A direction of travel of the tick marks may be identified, to determine whether the programmed dosage is increasing or decreasing. The apparatus may be arranged to identify a baseline dosage amount using a camera image of the medicament dosage indicator, so that a starting point for the count of tick marks can be determined. The medicament delivery device may be an injector pen.

Abstract: Compounds of formula (1): wherein R1 represents a —C(R2)(R3)—[C(R4)(R5)]m-L-R6 group or —R7; and the preparation and the therapeutic uses of the compounds of formula (1) as agonists of TRPM8 receptors, useful especially in the treatment of oropharyngeal dysphagia.

Abstract: A supplementary device configured to be releasably attached to an injection device includes at least one wireless communication unit and at least one sensor, wherein the supplementary device is configured to activate the at least one sensor in response to receipt via the at least one wireless communication unit of a wireless communication from an external device, following activation, to use the at least one sensor to detect the start of an injection by the injection device, and to communicate, via the at least one wireless communication unit, the start of the injection to the external device.

Abstract: An autoinjector includes a case configured to receive a syringe, a slidable member that is movable axially within the case to cause at least a portion of the syringe to move axially when the syringe is disposed within the case for dispensing a medicament through a needle of the syringe, a locking member configured to prevent actuation of the slidable member when the autoinjector is in a pre-dispense configuration, a sleeve coupled to a distal end of the case and surrounding at least a portion of a needle of the syringe when the syringe is disposed within the case, an elongate member extending proximally from the sleeve and configured to deflect the locking member to allow actuation of the plunger, and two drive springs coupled to the slidable member and configured to apply a biasing force that acts on the slidable member to move the slidable member distally.

Abstract: Provided herein are methods for the treatment of Alport syndrome, using a modified oligonucleotide targeted to miR-21. In certain embodiments, the modified oligonucleotide targeted to miR-21 improves kidney function and/or reduces fibrosis in subjects having Alport syndrome. In certain embodiments, administration of the modified oligonucleotide targeted to miR-21 delays the onset of end-stage renal disease in a subject having Alport syndrome. In certain embodiments, the modified oligonucleotide targeted to miR-21 delays the need for dialysis or kidney transplant in a subject having Alport syndrome.

Abstract: The present technology relates to a polypeptide comprising at least three immunoglobulin single variable domains (ISVDs). In particular, the present technology relates to a polypeptide comprising an optimized ISVD binding to fractalkine receptor CX3CR1 and an optimized ISVD binding to albumin. The present technology also relates to a composition of a polypeptide; a polynucleotide encoding a polypeptide; a host or host cell comprising a polynucleotide; a method for producing a polypeptide or composition; and a polypeptide, polynucleotide or composition for use in prevention, therapy and diagnosis of a disease or disorder.

Abstract: An autoinjector includes a case, a syringe carrier slidably disposed within the case and adapted to hold a syringe including a stopper, a plunger slidably disposed within the syringe carrier and adapted to apply a force on the stopper, and a drive spring disposed within the plunger and biasing the plunger relative to the syringe carrier.

Abstract: A packaging assembly includes a case configured to at least partially contain injection devices for delivering a medicament; a light sensor configured to detect light incident on the packaging assembly; and a status indicator configured to generate an output which indicates a status of the packaging assembly conditional on an intensity of light detected by the light sensor exceeding a threshold light intensity.

Abstract: The present invention relates to polypeptide variants of porcine trypsin, to nucleic acid molecules encoding these variants, and to host cells comprising such nucleic acid molecules. It also relates to the use of these variants in methods for producing insulin. The invention further relates to the use of these variants as medicaments, as food ingredients, or as feed ingredients and to the use of these variants within a process of manufacturing a food ingredient or a feed ingredient.

Abstract: The present technology provides immunoglobulin single variable domains (ISVDs) binding both the constant domain of a human T cell receptor (TCR) on a T cell and the constant domain of a non-human primate TCR on a T cell. It also relates to polypeptides comprising an ISVD according to the present technology and at least one ISVD capable of binding to an antigen on a target cell. The present technology further provides nucleic acids encoding said ISVDs or polypeptides as well as vectors, hosts and methods to produce these ISVDs or polypeptides. Moreover, the present technology relates to methods for treatment making use of the ISVDs or polypeptides of the present technology.

Abstract: A packaging assembly comprises a case configured to at least partially contain a plurality of injection devices for delivering a medicament; a light sensor configured to detect light incident on the packaging assembly; and a wireless communication module configured to establish a wireless connection with at least one external device conditional on an intensity of light detected by the light sensor exceeding a threshold light intensity.

Abstract: An injector device includes an elongate housing configured to receive container of medicament. The injector device also includes a needle sleeve mounted within the housing and moveable between an extended position in which the needle sleeve at least partially extends from the distal end of the housing, and a retracted position in which the needle sleeve is received further within the housing than in the extended position. The injector device also includes a release mechanism configured to control actuation of a piston rod. The release mechanism includes a rotatable member disposed within the housing and in cooperating engagement with the needle sleeve such that movement of the needle sleeve from the extended position to the retracted position causes the rotatable member to rotate within the housing from a first position to a second position.

Abstract: A data collection device comprises: a first portion having one or more features configured for attaching of the first portion to a dosage knob of an injection device; a second portion rotatably coupled with the first portion, wherein at least part of the second portion is movable axially relative to the first portion; a sensor arrangement configured to detect rotation of the first portion relative to the second portion; and a processor arrangement configured to, based on said detected movement, determine a medicament amount expelled by the injection device, wherein the coupling arrangement is configured to provide a non-permanent coupling between the first portion and the dosage knob of the injection device.

Abstract: The present application relates to compounds of formula (I), or pharmaceutically acceptable salts thereof: wherein R1 and R2 represent hydrogen or deuterium; R3 represents hydrogen, —COOH or —OH; R3? and R3? represent hydrogen, methyl, methoxy, chlorine, fluorine or cyano; R4 and R41 represent hydrogen or fluorine; R5 represents hydrogen, fluorine or (C1-C3)alkyl; R6 represents phenyl, fused phenyl, bicyclic group comprising 5 to 12 carbon atoms, heteroaryl group comprising 2 to 9 carbon atoms and comprising from 1 to 3 heteroatoms, cycloalkyl group comprising 3 to 7 carbon atoms, (C3-C6)cycloalkyl(C1-C3)alkyl group, 3 to 8 membered-heterocycloalkyl group comprising 1 or 2 heteroatoms, (C1-C6)alkyl, and phenyl(C1-C2)alkyl group; X represents —CH2—, —O— or —S—; Y represents —CH?, —N? or —CR??, wherein R? represents (C1-C3)alkyl, halogen, cyano, or (C1-C3)fluoroalkyl; R7 represents (C1-C3)alkyl, halogen atom, cyano, or (C1-C3)fluoroalkyl; R8 represents hydrogen or fluorine; R9 represents hydrogen, (C1-C3)alkyl